Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36.
J VirolAug 21, 2026 (epub)
Jade Alvarez, Pola Olczak, Hua-Ling Tsai et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated the immunogenicity of 20 µg AAV2-like particles displaying HPV L2 residues in 20 healthy subjects. The vaccine was well tolerated and induced modest L2-specific serum antibody titers that neutralized HPV16, HPV31, and HPV5. Notably, three doses were required for HPV16-naïve individuals to achieve protection, while previously exposed individuals needed only two doses.
Key findings
- AAVLP-HPV vaccination induced modest L2-specific serum antibody titers.
- Three doses were needed for HPV16-naïve patients to develop protection.
- Prior exposure to AAV2 reduced the strength and duration of the neutralizing antibody response.
- Sera from vaccinated patients conferred protection against HPV16, HPV31, and HPV5 in mice.
Why it matters
Understanding the factors influencing vaccine-induced immunity is crucial for developing effective HPV vaccines. This study highlights the impact of prior infections on vaccine response, which may inform future vaccination strategies and improve protective outcomes.